Concert Pharmaceuticals NASDAQ:CNCE Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.

Location: 65 Hayden Ave Ste 3000N, Massachusetts, 02421-7994, US | Website: www.concertpharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing